Genetics of Atrial Fibrillation in the Framingham Heart Study. Population in Primary Prevention

弗雷明汉心脏研究中心房颤动的遗传学。

• 批准号: 53326744
• 负责人: Professorin Dr. Renate B. Schnabel
• 金额: --
• 依托单位: Framingham Heart Study
• 依托单位国家: 德国
• 项目类别: Research Fellowships
• 财政年份: 2007
• 资助国家: 德国
• 起止时间: 2006-12-31 至 2008-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/53326744?language=en
• 关键词: Genetics; Atrial; Fibrillation; Framingham; Heart

Atrial fibrillation (AF) is the most common disabling cardiac arrhythmia leading to stroke and heart failure. Despite its increasing socioeconomic relevance in a modern population data on predisposing risk factors and triggers are scant. The Framingham Heart Study (FHS) is synonymous with the remarkable advances made in the prevention of cardiac disease throughout the world. Directly addressed research questions will be the prevalence and incidence of AF. The study design allows a comprehensive research of the genetics of atrial fibrillation in initially healthy individuals in context with anamnestic, environmental, clinical, and electrocardiographical factors. To investigate the genetic factors associated with AF risk complementary approaches are chosen; a) candidate genes of inflammatory and cardiac remodelling pathways are examined; and b) - most importantly - genome wide association studies using 100K (potentially 550 K) genome scans will be applied; c) finally a prediction model for the risk of developing AF will be developed. Replication and validation of the obtained genetic data will be performed after return to Germany in the PREVENT-it Study, Johannes Gutenberg-University, Mainz, a population-based prospective study comprising 17.000 German individuals providing clinical, genetic, and proteomic parameters.

心房颤动（AF）是最常见的致残性心律失常，可导致中风和心力衰竭。尽管其在现代人口中的社会经济相关性越来越大，但关于诱发风险因素和触发因素的数据却很少。心脏病研究（FHS）是全世界心脏病预防方面取得的显著进展的代名词。直接解决的研究问题将是房颤的患病率和发病率。研究设计允许在既往、环境、临床和心电图因素的背景下，对最初健康的个体进行房颤遗传学的全面研究。为了研究与AF风险相关的遗传因素，选择了补充方法; a）检查炎症和心脏重塑途径的候选基因;以及B）最重要的是，将应用使用100 K（可能550 K）基因组扫描的全基因组关联研究; c）最后将开发用于发展AF风险的预测模型。在返回德国后，将在美因茨约翰内斯古腾堡大学的PREVENT-it研究中对获得的遗传数据进行复制和验证，这是一项基于人群的前瞻性研究，包括17.000名德国个体，提供临床、遗传和蛋白质组学参数。